Ibogaine and alcohol addiction are connected through a specific neurological mechanism that no other available treatment addresses directly. Chronic alcohol use depletes GDNF — a protein that supports dopamine neuron survival in the brain's reward centre. Ibogaine upregulates it. That is the core of the mechanism. The evidence across observational studies is consistent in direction, if not yet conclusive by clinical trial standards. The contraindications for ibogaine in alcohol-dependent individuals include one that applies to this population specifically and that has been fatal when ignored.
Ibogaine interrupts alcohol dependence by upregulating GDNF (Glial Cell Line-Derived Neurotrophic Factor) in the ventral tegmental area — the brain's reward centre. Chronic alcohol use depletes GDNF and damages dopamine signalling. A single ceremony can substantially reduce craving, with the active metabolite noribogaine sustaining the effect for weeks. Alcohol-dependent candidates must complete a supervised medical taper before ceremony is possible.
How Ibogaine Interrupts Alcohol Dependence
Chronic heavy drinking degrades the brain's dopamine system. The primary site of damage is the ventral tegmental area (VTA) — the brain's central dopamine production centre and the hub of its reward circuitry. Repeated alcohol exposure depletes GDNF (Glial Cell Line-Derived Neurotrophic Factor), a protein critical to dopamine neuron survival and function. As GDNF levels fall, dopamine signalling becomes dysregulated. The cycle of craving and consumption becomes neurobiologically entrenched, not merely habitual.
Ibogaine reverses this through a specific, documented mechanism. A 2005 study in the Journal of Neuroscience demonstrated that ibogaine upregulates GDNF in the VTA — and that this increase directly reduces ethanol self-administration. The researchers microinjected GDNF into the VTA, reproducing ibogaine's effect. They then neutralised GDNF with antibodies, eliminating it. The pathway is not incidental.
Noribogaine — ibogaine's active metabolite — sustains this GDNF upregulation for days to weeks after ceremony. Research from the Bonci laboratory at UCSF documented a positive feedback loop in which GDNF triggers its own continued expression. This is the most plausible explanation for why ibogaine's effects on alcohol craving persist well beyond the 12–24 hour active experience.
Ibogaine also disrupts the default mode network — the brain's self-referential processing loop associated with craving, anticipation, and rationalisation. That disruption creates a period during which the patterns sustaining the addiction are less fixed and new ones more accessible. The period is real and time-limited. What is done with it determines whether any lasting change follows.
What the Research Shows
The clinical evidence on ibogaine and alcohol is less extensive than the evidence for opioid dependence, but consistent in direction. A 2018 study (Noller et al.) followed 30 patients with severe alcohol dependence through ibogaine treatment. At two to four weeks post-treatment, participants reported significant reductions in craving. A proportion maintained abstinence at 12 months above what standard care typically produces. An open-label clinical trial registered with ClinicalTrials.gov (NCT03380728) has been assessing escalating ibogaine doses specifically for alcohol use disorder.
The 2023 Stanford study, published in Nature Medicine, is also relevant here. Its population of 30 special operations veterans had comorbid conditions that included substance use disorders. The study documented 88% average reductions in PTSD symptoms, 87% in depression, and 81% in anxiety at one month post-treatment. The veterans in that study had been through programmes. They had been given diagnoses and medications. Many were sceptical that anything was going to work. The Stanford numbers documented what practitioners had been observing for years — that ibogaine produces changes in treatment-resistant populations that conventional approaches do not.
The people who arrive at ibogaine for alcohol addiction after years of other approaches share a consistent pattern. AA for years — sometimes useful, sometimes not sufficient. Naltrexone or acamprosate — some effect on craving, not enough to hold long-term. Residential programmes — months of abstinence, followed by a return to the same environment. By the time they reach ibogaine, they are not naive about difficulty. They have evidence that the available options have not been enough for them. That kind of scepticism — earned across years — tends to produce people who are prepared to work with what the ceremony shows them.
The evidence as it stands is consistent without being definitive. No placebo-controlled, double-blind clinical trial on ibogaine and alcohol has been completed. The observational data is what exists. It points consistently in one direction, in populations where conventional treatment had demonstrated its limits.
Why Alcohol Withdrawal Requires Special Preparation
This applies specifically to alcohol and is not standard in most ibogaine content. It should be.
Ibogaine cannot be safely administered to someone who is acutely alcohol-dependent and has recently stopped drinking without medical supervision. Alcohol and benzodiazepine withdrawal are among the few withdrawal syndromes that can be fatal. Unlike opioid withdrawal — uncomfortable but not lethal in otherwise healthy adults — abrupt cessation in someone with significant physical alcohol dependence can cause grand mal seizures within 24–72 hours. Those seizures can kill.
Anyone with significant physical alcohol dependence cannot simply stop drinking and proceed to ceremony. A supervised medical taper is required first — typically managed with benzodiazepines under physician oversight. The taper duration depends on consumption history and dependence severity. It may take one to three weeks. This step cannot be shortened, self-managed, or skipped.
A provider who accepts an alcohol-dependent candidate who has not completed a supervised taper is not operating safely. There is no case in which that is acceptable.
Chronic alcohol use also damages the liver. The liver metabolises both ibogaine and noribogaine. Impaired function slows clearance, extends the active experience, and increases the cardiac risks ibogaine already carries. A full liver panel — including AST, ALT, ALP, total protein, albumin, and total bilirubin — is required for every candidate with an alcohol use history. People with years of heavy use should not assume their liver function is adequate. The panel tells you, not the assumption.
What Medical Screening Requires
Every candidate for ibogaine ceremony at ExploreBwiti in Vancouver requires medical screening before ceremony is possible. This is not a formality — it is how we identify the candidates for whom ibogaine carries risks that the experience itself cannot resolve.
Required for all candidates:
- Full medical history
- EKG and cardiovascular assessment. Ibogaine prolongs the QT interval. This is how you identify, before ceremony, the candidates for whom that prolongation is dangerous. Any provider who skips this step is not operating safely — the fatalities that have occurred during ibogaine treatment are concentrated among providers who did not screen for cardiac contraindications.
- Blood panel (liver function, kidney function, CBC)
- Review of all current medications
- Psychiatric history assessment
Additional requirements for candidates with alcohol use history:
- Complete liver panel (AST, ALT, ALP, total protein, albumin, total bilirubin)
- Confirmation of completed supervised alcohol taper — with documentation from the supervising physician
Providers charging significantly below market rates are almost always reducing the safety infrastructure that accounts for the cost. The on-site medical professional, the pre-ceremony cardiac monitoring, and the physician oversight during the 12–24 hour ceremony are what the price reflects. A $500 ibogaine ceremony is not a bargain. Something is missing.
We respond to every application personally within 2–3 business days.
The Integration Window — and What Determines Outcomes
Ibogaine is not a cure for alcohol addiction. It is a neurological reset — a window during which craving is reduced and new patterns are more possible. What happens in that window is entirely dependent on what the person does with it. Ibogaine ceremony followed by a return to the same environment, relationships, and unaddressed conditions that produced the addiction produces relapse.
This is not speculative. People leave ceremony with significantly reduced craving and a clarity that — for those with long histories of dependence — can feel unlike anything in years. Some of them are drinking again within six weeks. Because the environment has not changed. The relationships that enabled the drinking have not changed. And there was no structured support in place for the period when the neuroplasticity window was open and relapse risk was highest.
The window noribogaine sustains — typically 8–12 weeks after ceremony — is when the lasting work is done. Identifying the specific conditions that produced the addiction: the unaddressed trauma, the environmental triggers, the patterns of avoidance. Making deliberate changes to them. Integration coaching provides structure for this. It is not an optional addition to the ceremony — for people seeking lasting outcomes with alcohol, it is part of the same process.
Who This Is Not For
The following are absolute contraindications. They are not preferences or guidelines that can be weighed against motivation.
- Active alcohol dependence without a completed supervised medical taper. Someone who has stopped drinking in the last few days without medical oversight is not a safe candidate. The seizure risk from unsupervised alcohol withdrawal is real.
- QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction. Identified by EKG. Non-negotiable regardless of condition or motivation.
- Severe liver disease. Impaired liver function extends the active experience unpredictably and increases cardiac risk. Years of heavy alcohol use do not automatically mean severe liver disease — the panel confirms it. But it cannot be assumed away.
- Current SSRIs or SNRIs. The risk of serotonin syndrome from the interaction between ibogaine's serotonergic activity and active antidepressants is real and potentially fatal. A supervised taper with the prescribing physician is required. There are no exceptions.
- Active psychosis or schizophrenia spectrum disorder. Ibogaine amplifies what is present. Someone in acute psychiatric instability is not an appropriate candidate.
- Methadone without a specific supervised transition protocol. Transitioning from methadone to ibogaine is a specific clinical procedure. It is not a wash-out period.
- Pregnancy.
Someone in acute crisis — regardless of how urgently they need help — is not an appropriate candidate for ceremony. The experience amplifies what is present. Entering it in crisis does not produce stability. If you are not an appropriate candidate, we will say so directly. We would rather lose a potential participant than put someone at risk.
The FAQ covers the full contraindication list and what the screening process involves.
Is This Right for You?
Ibogaine for alcohol addiction at ExploreBwiti is appropriate for people who have exhausted other options — residential treatment, naltrexone, acamprosate, sustained AA engagement, other pharmacological approaches — and have evidence that those approaches have not been sufficient. It is not a first-line option. It requires a completed alcohol taper, adequate cardiac and liver function, and a genuine commitment to the integration period that follows the ceremony.
If you are currently drinking at a level that constitutes physical dependence, the process begins with your physician and a supervised taper — not with an application to ceremony. When that taper is complete and your medical screening is ready, the conversation can proceed.
The FAQ covers screening requirements and disqualifiers in detail. The ceremony page explains what the 12–24 hour ibogaine experience and 2–3 day recovery period involve in Vancouver. Integration coaching is part of the process — not an add-on. When you are ready to begin the conversation, the application is where it starts. Every application receives a personal response within 2–3 business days.